Abstract:Shenghao Li, 1, 2, &ast Liyuan Hao, 1, 2, &ast Jiali Deng, 1, 2 Junli Zhang, 3 Fei Yu, 1, 2 Fanghang Ye, 1, 2 Na Li, 1, 2 Xiaoyu Hu 2 1 School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China; 2 Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China; 3 Department of Infectious Diseases, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaoyu Hu, Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, 610072, Sichuan Province, People's Republic of China, Email Hepatitis B virus (HBV) is a globally prevalent human DNA virus responsible for over 250 million cases of chronic liver infections, leading to conditions such as liver inflammation, cirrhosis and hepatocellular carcinoma (HCC). Sodium taurocholate co-transporting polypeptide (NTCP) is a transmembrane protein highly expressed in human hepatocytes and functions as a bile acid (BA) transporter. NTCP has been identified as the receptor that HBV and its satellite virus, hepatitis delta virus (HDV), use to enter hepatocytes. HBV entry into hepatocytes is tightly regulated by various signaling pathways, and NTCP plays an important role as the initial stage of HBV infection. NTCP acts as an initiation signal, causing metabolic changes in hepatocytes and facilitating the entry of HBV into hepatocytes. Thus, a comprehensive understanding of NTCP's role is crucial. In this review, we will examine the regulatory mechanisms governing HBV pre-S1 binding to liver membrane NTCP, the role of NTCP in HBV internalization, and the transcriptional and translational regulation of NTCP expression. Additionally, we will discuss clinical drugs targeting NTCP, including combination therapies involving NTCP inhibitors, and consider the safety of NTCP as a therapeutic target. Keywords: NTCP, HBV, HBV entry, Bulevirtide Hepatitis B virus (HBV) infection is a major global public health challenge. According to data from the World Health Organization (WHO) showed that in 2019, 290 million people were living with chronic hepatitis B (CHB) infection, and 1.5 million new infections were diagnosed each year. 1 As a prototype virus of the Hepadnaviridae family, HBV has partial double-linked ring DNA and encodes a variety of functional proteins. 2 Chronic HBV infection is a major cause of cirrhosis and hepatocellular carcinoma (HCC). 3 Currently, the primary treatments for HBV infection are nucleotide analogues (NAs) and interferons (IFNs). 4 Nucleotides and NAs inhibit the reverse transcription of pre-genomic RNA (pgRNA) into HBV DNA but are associated with the risk of drug resistance and often fail to achieve hepatitis B surface antigen (HBsAg) clearance. 5,6 Some cccDNA degradation can be achieved by immune-mediated degradation, such as interferon alpha, lymphosin-beta receptor agonists, tumor necrosis factor alpha, and interferon gamma, by upregating apolipoprotein B mRNA editing enzymes to catalyse cellular effectors such as apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3A/3B (also known as APOBEC3A/3B cytidine deaminase). The cccDNA is deammoniated in the nucleus. In addition, IFNs therapy can regulate innate and adaptive immunity and also affect the activity of HBV covalently closed circular DNA (cccDNA). However, it has the disadvantages of poor tolerance and serious side effects. While these treatments can help control HBV infection, long-term or even lifelong therapy is often required. Patients must also contend with high treatment costs, frequent disease monitoring, and strict adherence to their treatment regimen. Despite treatment, the risk of cirrhosis and liver cancer remains elevated. Therefore, the discovery of new anti-HBV drugs is very important and urgent. Given the current inability to completely eradicate cccDNA from infected liver nuclei, therapies have been developed to inhibit the entry, assembly and secretion of HBV and to clear cccDNA from infected liver cells. 7 In particular, in 2012, the cellular entry receptor for HBV, sodium taurocholate co-transporting polypeptide (NTCP), was discovered. NTCP is a transmembrane bile acid (BAs) transporter expressed in hepatocytes and also serves as the entry receptor for HBV's satellite virus, HDV. 7 This provides new clues to potential treatments -Abstract Truncated-

Structure of hepatitis B/D antiviral drug Bulevirtide bound to its receptor protein NTCP

Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP

Structural basis of hepatitis B virus receptor binding

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies

Structural basis for hepatitis B virus restriction by a viral receptor homologue

Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery

Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening

The Culprit Behind HBV-Infected Hepatocytes: NTCP

Role of sodium taurocholate cotransporting polypeptide (NTCP) in HBV-induced hepatitis: Opportunities for developing novel therapeutics

Clinical effects of NTCP‐inhibitor myrcludex B

Synthesis and evaluation of pentacyclic triterpenoids conjugates as novel HBV entry inhibitors targeting NTCP receptor

Identification of BST-2/tetherin-induced Hepatitis B Virus Restriction and Hepatocyte-Specific BST-2 Inactivation.

Structure-Activity Relationships and Discovery of ( S )-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6 H -pyrido[1,2- h ][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer

No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta

Efficient Inhibition of Hepatitis B Virus Infection by a Pres1-Binding Peptide

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Plerixafor and resatorvid inhibit hepatitis B virus in vitro by upregulating elongation factor Tu GTP-binding domain containing 2

Molecular Determinants of Hepatitis B and D Virus Entry Restriction in Mouse Sodium Taurocholate Cotransporting Polypeptide.

Structural and Functional Analyses of Hepatitis B Virus X Protein BH3-like Domain and Bcl-xL Interaction

Computational Evaluation of Abrogation of HBx-Bcl-xL Complex with High-Affinity Carbon Nanotubes (Fullerene) to Halt the Hepatitis B Virus Replication.